Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
about
Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysisA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.Novel long-acting bronchodilators for COPD and asthmaExacerbation rate, health status and mortality in COPD--a review of potential interventionsEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyOptimising treatment for COPD--new strategies for combination therapyDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function.Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Nebulized formoterol: a review of clinical efficacy and safety in COPD.Innovations to achieve excellence in COPD diagnosis and treatment in primary care.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?Future of chronic obstructive pulmonary disease management.Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD.Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?Defining phenotypes in COPD: an aid to personalized healthcare.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Long-acting muscarinic antagonists.Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.Triple Therapy for Chronic Obstructive Pulmonary Disease Management. Are Our Expectations Fulfilled?Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.
P2860
Q26800134-6AE2EE0B-CF1D-421C-B318-65CE1F911775Q26801661-44ADF67B-1151-456D-AEB0-03256FCCF834Q27012625-05073370-9788-4B30-85AF-8666C662D76EQ30238494-9EC73ED9-B985-4ED6-8DF7-199EAE37309CQ33743284-6C4A75DD-9DA8-4B0C-A2E8-0286CFD9CBBCQ34423324-05D8C995-D531-4249-A617-8C1773ECEE75Q35703517-6E08A3C4-47D9-4AA7-8DC6-9ACBC534B52EQ35749377-AC23F5EF-7641-43AD-AFA1-B45E58B896C0Q35822151-534514FF-0C1F-440B-B9A4-FFD7F6CE3B60Q36376413-20891E37-C267-4D6E-B53F-E6C1A00176F2Q37208308-201E9056-EACD-4D57-980F-29F50E0274D6Q37236165-C88C753C-D488-4FB5-BB09-65A32806C4DCQ37247499-8755D110-A322-4CF0-BE45-2625AAA07B48Q37336771-146CBBC4-2CB6-4279-9813-457B8220DB69Q37351371-8EE73197-E3AE-4A59-882D-4606DF4AD381Q37622938-8E1D4934-2AFC-402A-B63C-21C9BC1579C0Q37667100-BD69AC48-18D6-463D-8626-184E1218F113Q37780450-A5759151-6222-4A02-B341-890DF3D003D8Q37791320-4E0FF374-3C5D-45FF-9E25-A439BABECA75Q37804908-828C4BC8-1C55-4CAC-BBE9-5081DE54785FQ37973132-37640284-6535-425C-80A5-3B926033FCFAQ37982432-E0222019-53FB-4EFD-B2BE-BDAAE5E3DD7BQ38025725-99B25A83-4E3E-4E1E-B22E-A6C2282A678CQ38070173-FE7AB874-7317-4D25-A210-69DCB0142C0FQ38095558-484A17D7-A671-4B1A-BD80-CA7002EB13F3Q38095559-C3EC5991-E707-450D-90FC-7D566271607BQ38208244-ECAAB8E8-7C8A-4404-BC46-4C78FB8969B0Q38266325-506E117B-1C0E-4AE2-A22E-E011969CD7A1Q38537326-F1354E3D-DDD8-4CD1-AE52-57DED101C8B1Q38586322-BDADC28A-B84F-4340-BC6F-C166701D4E7BQ38730318-165E267A-DA0E-4DBE-B454-299CFBAB19CBQ38947859-2F88701F-12C4-4AF2-99F2-EE4D8D4ACF18Q41018618-002307B6-2139-438C-8FBE-13929B4B00CEQ42776525-78DC124D-CC35-41BB-8A92-0A380E26991EQ43232363-358A8F7C-72B5-4DB7-A322-5D398FEE37A3Q46513467-C471C083-92D3-41E0-9397-747A01E2530EQ47661714-4E051153-0D87-48B8-85A1-E58A5DC8699FQ51599981-889AF1CA-99D8-471E-A7BB-A3701DA255A0
P2860
Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Comparison of a combination of ...... fluticasone in moderate COPD.
@en
type
label
Comparison of a combination of ...... fluticasone in moderate COPD.
@en
prefLabel
Comparison of a combination of ...... fluticasone in moderate COPD.
@en
P2093
P356
P1433
P1476
Comparison of a combination of ...... fluticasone in moderate COPD.
@en
P2093
Alexandros Sagkriotis
Klaus F Rabe
Klaus Viel
Wolfgang Timmer
P304
P356
10.1378/CHEST.07-2138
P407
P577
2008-04-10T00:00:00Z